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Summary Although tissue polypeptide-specific antigen (TPS) has been described as a potentially useful serum marker of tumour activity in
adult epithelial tumours, few data are available for childhood malignancies. Neuroblastomas and Wilms' tumours are the commonest types of
solid malignancies found in the retroperitoneum of children. At this time, a widely used marker for Wilms' tumour is not available. Using an
enzyme-linked immunosorbent assay (ELISA) kit, serum TPS levels in 23 children with neuroblastomas, nine with Wilms' tumours and 22 with
benign tumours were evaluated to test the usefulness of the marker in identifying malignancies. Compared with healthy children (n = 110), the
preoperative least-square means (LSM) of serum TPS were considerably elevated in both neuroblastoma (LSM = 209 U l-1) and Wilms'
tumour (LSM = 235 U 1-1), whereas values in benign tumours were only slightly elevated. Although the Wilms' tumours were associated with
higher preoperative serum TPS levels, there was no statistically significant difference compared with neuroblastomas. Receiver operating
characteristic analysis (ROC curves) showed a high sensitivity and specificity for both malignancies. Successful treatment resulted in
decrease in TPS serum values. Serum TPS measurements in children presenting with abdominal masses can help in diagnosing the two
commonest extracranial solid malignancies of childhood. Furthermore, TPS could acquire a pivotal role in monitoring therapy.
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The assay for tissue polypeptide-specific antigen (TPS) detects
soluble fragments of cytokeratin 18 (Rydlander et al, 1996), an
acid cytokeratin protein present in epithelial cells. Serum levels of
TPS can be measured with an enzyme-linked immunosorbent
assay (ELISA) that uses a high-affinity monoclonal antibody
against M3, one of 35 identified epitopes of the tissue polypeptide
antigen (TPA), which constitutes the specificity related to cell
proliferation (Einarsson et al, 1997). TPS, as evaluated in cell
culture supernatants, has been found to correlate with cell number
and DNA synthesis rate (Madersbacher et al, 1993).
Extensive studies have shown that TPS is useful in diagnosing
and monitoring adult epithelial tumours of the breast (Einarsson,
1995; Bremer et al, 1996; Giai et al, 1996), lung (Pujol et al,
1994), prostate (Kramer et al, 1997) and gastrointestinal tract
(Kornek et al, 1995). We have recently established normal values
for paediatric patients (Rebhandl et al, 1997a), but few data are
available as yet about TPS in paediatric malignancies. After
cerebral malignancies, neuroblastoma and Wilms' tumour are the
commonest solid tumours in childhood. They typically present as
an upper abdominal mass.
The aim of this study was to ascertain the role of TPS as a
tumour marker for neuroblastoma and Wilms' tumour and deter-
mine its capability to discriminate between these two entities, as
well as between benign and malignant tumours in general.
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MATERIALS AND METHODS
Patients
Over 250 serum samples from children with neuroblastoma,
Wilms' tumour or benign tumours (e.g. haemangiomas, liver cysts,
lymphangiomas) were evaluated for TPS content. All diagnoses
were confirmed by pathohistology, as all patients had been
referred to our department for surgery. In the presence of sepsis or
renal insufficiency, TPS values are elevated (Rebhandl et al,
1997b); these samples were, therefore, excluded.
We included 23 neuroblastomas (ten boys, 13 girls; mean age
2.2 years; range 2 weeks to 10.8 years), nine Wilms' tumours (four
boys, five girls; mean age 3.7 years; range 7 weeks to 6.8 years)
and 22 benign tumours (11 boys, 11 girls; mean age 2.3 years;
range 2 weeks to 7.9 years) in the study.
Patients were grouped into four categories (n = number of
samples):
* TPS 1: at the time ofdiagnosis/before therapy (neuroblastoma
n = 20; Wilms' tumour n = 8; benign tumours n = 22).
* TPS 2: during and at least 24 h after preoperative chemo- and/or
radiotherapy (neuroblastoma n = 15; Wilms' tumour n = 9).
Chemotherapy followed the 'Austro-Hungarian Wilms' Tumour
Protocol 89' and the 'Austrian Neuroblastoma 94 Study'.
* TPS 3: at least 24 h after surgical resection (neuroblastoma
n = 12; Wilms' tumour n = 7).
* TPS 4: in complete remission (neuroblastoma n = 4; Wilms'
tumour n = 0).
The same age groups from a previous study of 361 healthy chil-
dren (Rebhandl et al, 1997a) were used as a control (median TPS
serum values: 1 week to 1 year 88 U 1-1; 1-8 years 51 U 1-1; 8-18
years 34 U 1-').
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Table 1 Back-transformed least-square means (LSM) and corresponding 95% confidence intervals (Cls) of serum TPS values in defined conditions (U 1-1) of
neuroblastomas and Wilms' tumours. Serum TPS median values (M) and interquartile range Q1-Q3 (IQR) of benign tumours
No. No. TPS 1 TPS2 TPS 3 TPS4
patients samples
LSM Cl LSM Cl LSM Cl M IOR
Neuroblastoma 23 51 209 129-339 79 50-127 72 54-96 43 33-64
Wilms'tumour 9 24 235 128-429 104 68-159 89 58-137 n.d. n.d.
M IQR
Benign tumour 22 43 61 24-101
TPS 1, before treatment; TPS 2, during chemo- and/or radiotherapy; TPS 3, after surgical resection; TPS 4, no evidence of disease (complete remission).
Methods RESULTS
Venous blood samples (without additives), obtained from routine
blood tests, were centrifuged for 10 min at 1500 r.p.m. within 2 h
of drawing. The supernatant (500 gl) was deposited at -70°C. For
analysis, we measured serum TPS levels (U 1-') by applying M3
monoclonal antibody in an ELISA kit (Beki Diagnostics, Bromma,
Sweden). Each serum sample was tested in duplicate as recom-
mended by the manufacturer. The coefficients of variation
between the tests were 3.6% and 8.7%, respectively, as determined
by two control samples with low and high concentrations ofTPS.
Statistical analysis
Serum TPS levels for patients with neuroblastomas and Wilms'
tumours were measured at four different time points (TPS I-TPS
4). In cases ofmultiple measurements ofa patient at the same time
point, TPS levels were averaged.
Analysis of variance for repeated measurements with unstruc-
tured variance-covariance matrix was used to test for differences
between the first three categories (TPS 4 was excluded because of
the paucity of observations) and influence of age on TPS levels.
The least-square means (LSM), as computed by this method, can
be interpreted as means at each time point, assuming the same
underlying age distribution. Because TPS values were skewed to
the right, a logarithmic transformation was used. The least-square
means and corresponding 95% confidence intervals (CIs) given in
the text have been transformed back to original scale. For TPS 4
and benign tumours, median and interquartile range are given. For
multiple pairwise comparisons, data were adjusted according to
Tukey. We used SAS 1990 statistical software (SAS Institute,
SAS/STAT User's Guide, Version 6, Cary, NC, USA).
TPS values measured before treatment (TPS 1) were considered
to indicate the presence or absence of malignant tumours. By
assuming that subjects with marker levels exceeding a defined cut-
off value are positive while all others are negative and comparing
the results thus obtained to the verified diagnostic status of the
same patients, the diagnostic value of the marker can be summa-
rized in terms of sensitivity (the probability of a true-positive test)
and specificity (the probability of a true-negative test). Plots of
sensitivity vs 1 - specificity with varying cut-off levels for the
marker, i.e. receiver operating characteristic (ROC) curves (Zweig
et al, 1993), were calculated for TPS 1 values of patients with
neuroblastomas, Wilms' tumours and benign tumours, each
compared with tumour-free patients and stratified for age groups
(0-1 and 1-8 years).
Table 1 shows least-square means (LSM) of serum TPS and 95%
CIs in defined conditions ofneuroblastomas, Wilms' tumours and
benign tumours. Among the group with neuroblastomas, pretreat-
ment levels (TPS 1) were markedly elevated (LSM = 209 U 1-'),
followed by significant decline both during chemotherapy (LSM =
79 U 1-', P = 0.0172) and after surgery (LSM = 72 U 1-', P =
0.0017). Complete remission (TPS 4) was associated with a low
serum TPS level (median = 43 U 1-'). The patients with Wilms'
tumours had the highest TPS I levels (LSM = 235 U 1-'), which
also decreased during chemotherapy (TPS 2; LSM = 104 U 1-', P=
0.148) and dropped significantly after surgical resection (TPS 3;
LSM=88U1-',P=0.0463).
An age dependence of TPS levels was observed neither with
neuroblastomas nor with Wilms' tumours. Preoperative TPS levels
were higher in Wilms' tumours than in neuroblastomas, but this
difference was not statistically significant.
Figure IA shows ROC plots for sensitivity and specificity of
various serum TPS levels, differentiating between healthy children
< 1 year ofage and children with untreated neuroblastoma (TPS 1)
or benign tumour.
Figure lB indicates the accuracy of the marker in separating
healthy children aged 1-8 years from untreated patients with
neuroblastoma, Wilms' tumour or benign tumour (all TPS 1).
As is apparent from both ROC curves (Figure 1), TPS displays a
high degree of discriminating power in both age groups for
patients with neuroblastomas and Wilms' tumours, but not for
patients with benign masses.
DISCUSSION
Tumour markers for the diagnosis and monitoring of Wilms'
tumour are urgently needed. While attention has been drawn to the
great potential of TPA as a cytokeratin marker in Wilms' tumours
(Ishiwata et al, 1991), this interesting finding appears to have gone
unnoticed in the literature. Reports on clinically useful markers are
not available. NSE (neuron-specific enolase) is useful in the initial
screening for neuroblastoma, but the finding of elevated serum
NSE levels does not exclude the diagnosis of Wilms' tumour
(Pritchard et al, 1987), which is also well demonstrated immuno-
histochemically (Ellison et al, 1996).
So far, only indicative data have been available about TPS in
neuroblastomas or Wilms' tumours (Rebhandl et al, 1997b). The
present study provides a detailed analysis of serum TPS of neuro-
blastomas and Wilms' tumours at different treatment periods.
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Figure 1(A) Analysis by receiver operating characteristics (ROC) showing
the sensitivity and specificity of various preoperative serum TPS levels (TPS
1), differentiating between healthy children < 1 year of age and children with
untreated neuroblastomas (NB) or benign tumours (BT). (B) ROC plot
showing the sensitivity and specificity of various serum TPS levels,
comparing healthy children aged 1-8 years with preoperative serum values
(TPS 1) of children of corresponding age with neuroblastomas (NB), Wilms'
tumours (WT) or benign tumours (BT)
Normal values for serum TPS in healthy children of various age
groups have been published elsewhere (Rebhandl et al, 1997a).
Normal children apparently show an age-dependent variation, with
higher values in infants, adjusting to adult values with adolescent
age (Rebhandl et al, 1997a). Sepsis or renal dysfunction can have
repercussions on TPS levels and must be taken into account.
Cytokeratin expression has been described mainly for cells of
epithelial origin. The cytokeratin phenotype is well described in
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fetal kidney and is thought to be similar in the tubules of nephro-
blastoma (Giovagnoli et al, 1994; Ellison et al, 1996; Sainio et al,
1997). Only a few investigators have reported high serum TPS
levels in cytokeratin-negative tumours (Norton et al, 1987;
Ramaekers et al, 1988; Liu et al, 1992). Although immunofluores-
cence patterns are known to change in some malignancies (Skalli et
al, 1991), very little is known about the cytokeratin expression or
release by neuroblasts. Altemnatively, the Schwannian (Guarino et
al, 1993) or the myofibroblastic stroma cells ofthe neuroblastomas
might be responsible for cytokeratin release (Coffin et al, 1996).
Our findings show that serum TPS levels in children with
neuroblastomas or Wilms' tumours are considerably elevated
before treatment. A significant correlation between age and serum
TPS levels was not observable in these children. These results are
in contrast to a control group of normal children (Rebhandl et al,
1997a), which was characterized by age-related variance in TPS
levels.
The number ofcases assessed so far is too small to calculate any
correlation between prognostic factors and TPS values, especially
in neuroblastoma, in which the number ofpredictors is large (Saito
et al, 1997). Nevertheless, in children with Wilms' tumours it
seems that unfavourable histology is generally associated with
higher TPS values.
In both the patients with neuroblastomas and those with Wilms'
tumours, serum TPS levels dropped clearly during chemo- and/or
radiotherapy (Table 1). It remains unclear whether this decrease is
due to the cytostatic effect oftherapy. Removal of a neuroblastoma
or Wilms' tumour significantly decreased the individual serum
levels of TPS, suggesting that the source of serum TPS is present
in the tumour tissue.
The usefulness of serum TPS determinations in the diagnosis of
neuroblastoma and Wilms' tumour is apparent from the high sensi-
tivity and specificity ofthis marker, as reflected in our ROC curves
(Figure 1). The areas under the curves indicate the probability at
which a randomly selected patient with neuroblastoma, Wilms'
tumour or benign tumour has a higher serum TPS value than a
randomly chosen healthy child from the same age group.
Assessment of serum TPS levels in our patients enabled us to
differentiate between benign and malignant tumours. Children
with benign tumours were not noticeably different from healthy
children in terms of serum TPS levels, as apparent from the low
sensitivity and specificity obtained by ROC analysis.
To summarize, serum TPS level is a promising tool for distin-
guishing between malignant retroperitoneal tumours and benign
masses. The ELISA kit allows quick, sensitive and easy-to-
perform assessment. Furthermore, serum TPS could acquire an
important role in therapy monitoring.
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